Clinical trials: Bacterial Diseases
Cholera (Disorder)
VAXCHORA Pediatric Study to Assess Safety and Immunogenicity
VAXCHORA (Cholera Vaccine, Live, Oral) is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1.
- Trial name
- NCT03220737
- Testing
- VAXCHORA (Cholera Vaccine, Live, Oral)
- Where
- 10 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Aspergillosis
Study of FK463 for the Treatment of Invasive Aspergillosis
The purpose of the study is to evaluate the safety and efficacy of FK463 in patients with proven or probable invasive infections due to Aspergillus species.
- Trial name
- NCT00036166
- Testing
- FK463
- Where
- 23 sites in Austria, France and 6 more
- Volunteers
- 326 people
- Sponsor
- Astellas Pharma Inc
Meningococcal Disease
Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers
Evaluate the immune response and reactogenicity of one dose of Meningococcal ACWY-cross reactive material (CRM) and Meningococcal ACWY-tetanus toxoid (TT) in 12-15 months old healthy toddlers.
- Trial name
- NCT01994629
- Testing
- MenACWY-CRM, MenACWY-TT
- Where
- 4 sites in Italy
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pneumococcal Infections, Streptococcal Infections
Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)
Streptococcus pneumoniae is a major cause of morbidity and mortality in children worldwide, resulting in up to 1 million pediatric deaths every year.Since the licensure of PCV7 and PCV13,the reported overall decline in invasive…
- Conditions
- Pneumococcal Infections, Streptococcal Infections, Bacterial Infections
- Trial name
- NCT04841369
- Testing
- 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
- Where
- China
- Volunteers
- 3,420 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Covid19, Bacteremia
Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia
Phage Treatment in Covid-19 Patients with Bacterial Co-Infections
- Conditions
- Covid19, Bacteremia, Septicemia, Acinetobacter Baumannii Infection
- Trial name
- NCT04636554
- Testing
- Phage Therapy
- Sponsor
- Adaptive Phage Therapeutics, Inc.
Bacterial Infections
PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment
A Phase 1, open-label, single-dose study to determine the safety and pharmacokinetics of ORAvance (ceftibuten/xeruborbactam oral prodrug [QPX7831]) in participants with renal impairment
- Trial name
- NCT06157242
- Testing
- Xeruborbactam Oral Prodrug, Ceftibuten
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Qpex Biopharma, Inc.
Bacterial Infections, Bacterial Infections and Mycoses
Large Algorithm Setting and Validation Study
In this pilot study, prospectively acquired clinician-collected and participant-collected vaginal swab specimens will be obtained from up to 1000 individuals with signs and symptoms of vaginitis to develop and validate a…
- Conditions
- Bacterial Infections, Bacterial Infections and Mycoses, Infections, Vaginitis
- Trial name
- LAVA (NCT07607470)
- Testing
- Nanopath Vaginitis Assay, BD Max™ Vaginal Panel, Cepheid Xpert® Xpress MVP
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Nanopath, Inc
Infections, Meningococcal
Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine
The purpose of this study is to compare the immediate and long term (up to 5 years) immunogenicity and safety of GSK Biologicals' MenACWY-TT vaccine when given as a single dose or as 2 doses to toddlers aged 12 to 14 months.
- Trial name
- NCT01939158
- Testing
- Meningococcal vaccine GSK134612, Prevenar 13™
- Where
- 51 sites in Australia, Canada and 4 more
- Volunteers
- 803 people, healthy volunteers welcome
- Sponsor
- Pfizer
Clostridium Difficile Infection
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
The purpose of this research study is to evaluate the safety and effectiveness of a new oral antibiotic called SMT19969 in treating C. difficile Infection (CDI).
- Trial name
- NCT02092935
- Testing
- SMT19969, Vancomycin
- Where
- 26 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Summit Therapeutics
Pneumococcal Disease, Invasive
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13
The goal of this clinical trial is to evaluate the immunogenicity and safety of a novel 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13-TT) as compared to Pfizer's 13-valent pneumococcal conjugate vaccine (PCV13)…
- Trial name
- NCT05934890
- Testing
- Walvax PCV13-TT, Pfizer PCV13
- Where
- 2 sites in Indonesia
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
Meningitis, Meningococcal Infection
Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®
The study is designed to evaluate the persistence of bactericidal antibodies in subjects aged 7 to 15 years (not yet 16 years) who had been vaccinated five years previously in Study 603-02.
- Trial name
- NCT00258856
- Testing
- Polysaccharide Diphtheria Conjugate Vaccine
- Where
- 11 sites in United States
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Haemophilus Influenzae Type b
Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b
This study will investigate safety and immunogenicity of a monovalent conjugated vaccine against Haemophilus influenzae type b in healthy children aged 2 to 4 months in China.
- Trial name
- NCT00808392
- Testing
- Haemophilus influenzae type b vaccine, Commercial Haemophilus influenzae type b vaccine
- Where
- 2 sites in China
- Volunteers
- 916 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Tinea Pedis
Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis
Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis
- Trial name
- NCT03824912
- Testing
- Ketoconazole Cream 2%, Ketoconazole Cream 2% (G&W Laboratories Inc.)
- Where
- 9 sites in United States, Belize and 1 more
- Volunteers
- 831 people
- Sponsor
- Encube Ethicals Pvt. Ltd.
Hepatitis B, Polio
Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV
The purpose of this study is to document the immunological response to the investigational hexavalent vaccine at the 6, 10, and 14 weeks schedule The primary objective is to demonstrate that the hexavalent DTaP-IPV-HB-PRP~T…
- Conditions
- Hepatitis B, Polio, Diphtheria, Pertussis
- Trial name
- NCT00362336
- Testing
- DTaP-IPV-HB-PRP~T, CombAct-HIB®, Engerix B® Pediatric
- Where
- 2 sites in South Africa
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Non-Cystic Fibrosis Bronchiectasis
Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis "ORBIT-1"
The purpose of this study is to evaluate the safety and efficacy of Ciprofloxacin for Inhalation in the treatment of patients with non-cystic fibrosis (CF) bronchiectasis.
- Trial name
- NCT00889967
- Testing
- Ciprofloxacin for Inhalation
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 95 people
- Sponsor
- Aradigm Corporation
Infections, Meningococcal, Meningococcal Vaccines
Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects
The purpose of this study is to demonstrate, in 2-10 year old subjects, the non-inferiority of meningococcal vaccine GSK134612 compared to licensed meningococcal vaccine Mencevax™.
- Trial name
- NCT00514904
- Testing
- Nimenrix, Mencevax
- Where
- 7 sites in India, Lebanon and 2 more
- Volunteers
- 1,504 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Blood Stream Infection, Blood Stream Infections
Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test
This study is designed to evaluate the clinical performance of the UllCORE Bloodstream Infection (BSI) Test, an investigational molecular diagnostic test intended to detect microorganisms and selected antimicrobial resistance…
- Conditions
- Blood Stream Infection, Blood Stream Infections, Sepsis, Fungemia
- Trial name
- B-RAPID (NCT07859852)
- Testing
- UllCORE BSI Test
- Where
- 20 sites in United States, France and 3 more
- Volunteers
- 1,500 people
- Sponsor
- Deepull Diagnostics S.L.
Group B Streptococcal Infections
A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age
This is the Phase 1/2 first-in-human, randomized, placebo-controlled, observer-blinded study evaluating the investigational multivalent group B streptococcus vaccine.
- Trial name
- NCT03170609
- Testing
- Multivalent group B streptococcus vaccine
- Where
- 4 sites in United States
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- Pfizer
Staphylococcus Aureus, Bacteremia
Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)
This study will assess the efficacy of a single dose of V710 vaccine to prevent serious Staphylococcus aureus infections following elective cardiothoracic surgery.
- Conditions
- Staphylococcus Aureus, Bacteremia, Mediastinitis
- Trial name
- NCT00518687
- Testing
- V710
- Volunteers
- 8,031 people
- Sponsor
- Merck Sharp & Dohme LLC
Tuberculosis
To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.
The purpose of this study is to evaluate the safety, tolerability and effectiveness of TMC207 in combination with an individualized background regimen (BR) of antibacterial drugs as treatment for MDR-TB
- Trial name
- NCT00910871
- Testing
- TMC207, Background Regimen (BR) for MDR-TB
- Where
- 27 sites in China, Estonia and 10 more
- Volunteers
- 241 people
- Sponsor
- Janssen Infectious Diseases BVBA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.